Nampt/PBEF/visfatin in whole blood was 1.3-fold (1–1.8) lower in CRC patients than in controls (0.840 (0.69–1.02) versus 1.123 (0.93–1.36), p = 0.043). Here, NAMPT is linked to colorectal carcinoma.